Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Wakim

Nurse Practitioner, Primary Care Wheeling, WV Nurse Practitioner

NPI 1245536408 CMS profile 10823751

4 Linden Ave, Wheeling, WV 26003

Open in the dashboard

General payments

$169,471

299 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Wakim of Wheeling, WV is reported in the CMS Open Payments database as having received $169,471 across 299 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,800 81
2024 General $45,786 98
2023 General $69,640 48
2022 General $15,996 38
2021 General $18,249 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Wakim
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Amanda Wakim were reported at $19,800. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Amanda Wakim Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $18,249 $137 $39–$445 $132
2022 $15,996 $139 $44–$421 $149
2023 $69,640 $163 $53–$481 $160
2024 $45,786 $176 $54–$511 $164
2025 $19,800 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $133,326 93 payments
  2. Sanofi-Aventis U.S. LLC $27,433 57 payments
  3. Zealand Pharma US, Inc. $2,712 7 payments
  4. Corcept Therapeutics $1,524 13 payments
  5. Novo Nordisk Inc $1,512 65 payments
  6. Mannkind Corporation $1,340 35 payments
  7. Tandem Diabetes Care, Inc. $620 6 payments
  8. Amgen Inc. $245 12 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $170 2 payments
  10. Lilly USA, LLC $153 3 payments
  11. Other $437 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $152,965 94 payments
  2. Food and Beverage $7,614 173 payments
  3. Travel and Lodging $5,292 19 payments
  4. Consulting Fee $3,150 1 payment
  5. Education $272 9 payments
  6. Gift $178 3 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $90,510 64 payments
  2. TZIELD $27,064 53 payments
  3. MINIMED 770G $25,491 6 payments
  4. Minimed 770G System $16,775 3 payments
  5. ZEGALOGUE $2,031 4 payments
  6. Korlym $1,524 13 payments
  7. AFREZZA $1,340 35 payments
  8. RYBELSUS $605 47 payments
  9. t:slim X2 Insulin Pump with Control-IQ $535 5 payments
  10. Ozempic $531 47 payments
  11. Other $2,602 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

6,576

Median for Nurse Practitioner: 389

Drug cost

$3,207,037

Median for Nurse Practitioner: $21,885

Branded share of claims

59%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 617 $724,525
Trulicity Dulaglutide Brand 252 $333,000
Jardiance Empagliflozin Brand 264 $307,674
Mounjaro Tirzepatide Brand 218 $260,330
Farxiga Dapagliflozin Propanediol Brand 197 $216,799
Tresiba Flextouch U-200 Insulin Degludec Brand 133 $185,658
Repatha Sureclick Evolocumab Brand 123 $115,200
Humulin R U-500 Insulin Regular, Human Brand 59 $88,675
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 35 $77,585
Humalog Kwikpen U-200 Insulin Lispro Brand 26 $68,747

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$29,680

Medicare's payments for the services billed

Medicare patients

167

Average age 70

Services billed

404

88 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 40%
Chronic kidney disease 35%
Depression 33%
Heart failure 28%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $18,649
$18,649 — —
AFREZZA
  • Mannkind Corporation $589
$589 15 —
Korlym
  • Corcept Therapeutics $233
$233 — —
Repatha
  • Amgen Inc. $138
$138 146 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $123
$123 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record